Financial Performance - The company expects a net profit of -69 million CNY for the year 2025, compared to -50 million CNY in the same period last year[5] - Revenue is projected to be 2.75 billion CNY, slightly down from 2.85 billion CNY in the previous year, but an increase from 2.68 billion CNY two years ago[5] Market Competition - The company faces intensified competition in the ophthalmology market, impacting gross margins despite an increase in business volume and revenue in core areas[7] Policy Impact - The implementation of national policies for bulk procurement of artificial lenses continues to structurally affect revenue and profit margins in the cataract project[7] - The company is focusing on promoting advanced cataract surgeries to counteract the impact of price reductions due to policy changes[9] Strategic Expansion - The company is undergoing a strategic expansion with significant fixed costs, including depreciation and personnel expenses, which are currently pressuring overall profits[8] Technological Advancements - The introduction of new technologies, such as the Carl Zeiss SMILE Pro, has enhanced the average transaction value and driven revenue growth in refractive surgery[9] Investment Assessment - The acquisition of Dongguan Guangming Eye Hospital has led to a slowdown in revenue and profit growth, prompting the company to assess goodwill impairment for this investment[9]
普瑞眼科(301239) - 2025 Q4 - 年度业绩预告